Related Experiment Videos
MonoFIX-VF, a new mono-component factor IX concentrate: a single-centre continuous-infusion study
1Haemophilia Centre, Kent and Canterbury Hospital, Canterbury, Kent, UK. gillian.evans@ernt.nhs.uk
Summary
MonoFIX-VF is now the preferred treatment for factor IX deficiency in Australia. This study confirms its safety and effectiveness in managing bleeding episodes and surgical procedures in patients with haemophilia B.
Area of Science:
- Hematology
- Pharmacology
Background:
- Factor IX deficiency, also known as haemophilia B, requires effective clotting factor replacement therapy.
- Prothrombinex-HT was previously the standard treatment for factor IX deficiency in Australia.
- MonoFIX-VF, a monocomponent factor IX concentrate, has been introduced as a new treatment option.
Purpose of the Study:
- To assess the haemostatic efficacy and safety of MonoFIX-VF in patients with factor IX deficiency.
- To evaluate MonoFIX-VF's performance in managing bleeding episodes and surgical procedures.
Main Methods:
- A study was conducted involving four subjects with factor IX deficiency.
- MonoFIX-VF was administered via continuous infusion to treat 10 bleeding episodes.
- Treatment included five surgical procedures.
Main Results:
- MonoFIX-VF demonstrated a safe and effective haemostatic effect across all treated episodes.
- The treatment was well-tolerated by the subjects.
- Successful management of bleeding and surgical interventions was observed.
Conclusions:
- MonoFIX-VF is a safe and effective treatment for patients with haemophilia B.
- Continuous infusion of MonoFIX-VF provides adequate haemostasis for bleeding episodes and surgical procedures.
- MonoFIX-VF represents a valuable therapeutic option for factor IX deficiency.